Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Patent
1979-03-13
1980-02-26
Phillips, Delbert R.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
2601125S, A61K 37100, C07C10352
Patent
active
041906489
ABSTRACT:
Peptides having the structural formula: ##STR1## wherein A is D-Thr, D-Val;
B is D-Phe, D-Tyr;
C is D-Phe, D-Tyr, O-Me-D-Tyr;
wherein the ring formed by the peptide backbone contains 26 atoms and pharmaceutically acceptable non-toxic acid addition salts thereof are prepared by the solid phase method. These peptides have the property of inhibiting release of insulin, inhibiting growth hormone release and inhibiting glucagon release in humans and animals without materially affecting gastric secretion. They have a longer duration of action than somatostatin.
REFERENCES:
patent: 4146612 (1979-03-01), Veber
Immer, H., Proceeding of Fourteenth European Peptide Symposium, 471-476 (1976).
Shemyakin, M., et al., Angew Chem., Int. Ed. Engl., 8, 492-499 (1969).
Hazel Blondel
Merck & Co. , Inc.
Phillips Delbert R.
Rose David L.
Westlake Harry E.
LandOfFree
Peptides having somatostatin activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides having somatostatin activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides having somatostatin activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2113357